18337-64-9

Basic information

• Product Name: 4(1H)-Pyrimidinone, 6-hydroxy-5-phenyl-
• Synonyms: 4(1H)-Pyrimidinone, 6-hydroxy-5-phenyl-;5-phenylpyrimidine-4,6-diol
• CAS NO: 18337-64-9
• Molecular Formula: C₁₀H₈N₂O₂
• Molecular Weight: 188.18
• Mol File: 18337-64-9.mol

Chemical Properties

• Melting Point: 373-375 °C (decomp)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: 5.30±0.10(Predicted)
• CAS DataBase Reference: 4(1H)-Pyrimidinone, 6-hydroxy-5-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyrimidinone, 6-hydroxy-5-phenyl-(18337-64-9)
• EPA Substance Registry System: 4(1H)-Pyrimidinone, 6-hydroxy-5-phenyl-(18337-64-9)

Safety Data

• Hazardous Substances Data: 18337-64-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4(1H)-Pyrimidinone, 6-hydroxy-5-phenylis used as a building block for the synthesis of new drugs due to its potential biological activities. It is particularly valuable for the development of compounds with antimicrobial, antiviral, and anticancer properties, as it has been studied for these effects.
Used in Agricultural Industry:
In the agricultural sector, 4(1H)-Pyrimidinone, 6-hydroxy-5-phenylis utilized as a precursor in the synthesis of agrochemicals. Its potential use in this industry is attributed to its ability to contribute to the development of compounds with pesticidal or herbicidal activities, enhancing crop protection and yield.
Used in Antimicrobial Applications:
4(1H)-Pyrimidinone, 6-hydroxy-5-phenylis employed as an antimicrobial agent, leveraging its potential to inhibit the growth of various microorganisms, thereby contributing to the development of new antimicrobial drugs or treatments.
Used in Antiviral Applications:
4(1H)-Pyrimidinone, 6-hydroxy-5-phenylis also used in antiviral applications, where it may help in the development of antiviral drugs by targeting specific viral mechanisms or pathways, thus offering a new approach to combat viral infections.
Used in Anticancer Applications:
4(1H)-Pyrimidinone, 6-hydroxy-5-phenylis used as a component in the development of anticancer drugs, given its potential to exhibit anticancer activities. It may contribute to the creation of novel therapeutic agents that target cancer cells, offering new treatment options for various types of cancer.

Upstream product

• 3473-63-0 formamidine acetic acid 
• 83-13-6 diethyl 2-phenylmalonate 
• 10255-95-5 2-phenylmalonamide 
• 109-94-4 formic acid ethyl ester 
• 37434-59-6 dimethyl 2-phenylmalonate 
• 6313-33-3 formamidine hydrochloride 
• 77287-34-4 formamide 
• 103-82-2 phenylacetic acid 
• 101-41-7 benzeneacetic acid methyl ester 

Downstream Products

• 3974-16-1 4,6-dichloro-5-phenyl-pyrimidine 
• 885948-54-9 1-[(2-acetoxyethoxy)methyl]-4-hydroxy-5-phenylpyrimidin-6(1H)-one 
• 1393813-57-4 C₂₃H₂₁BrN₆O₄S 
• 441797-36-0 C₁₇H₁₅ClN₄O₂S 
• 1240108-41-1 4,6-dibromo-5-phenyl-pyrimidine 
• 926008-65-3 [4-(6-chloro-5-phenylpyrimidin-4-ylethynyl)phenyl]dimethylamine 

Relevant articles and documents

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

FUSED PYRIMIDINES AS AKT INHIBITORS

The present invention relates to compounds of formula (I), a N-oxide or tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6, R7, R10, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT-702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-ylpyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed.

Synthesis of new 5-substituted pyrimidine acyclonucleosides

Acyclonucleosides of pyrimidine were prepared by condensing appropriately silylated 5-substituted pyrimidines with an acyclic side chain in the form of an acetylated haloalkoxyalcohol and subsequent removal of the protecting acetyl group in base. Also, ac

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

Heterocyclic sodium/proton exchange inhibitors and method

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.